Dr. Myriam Mendila
Company: CureVac SE
Job title: Chief Scientific Officer and Head of R&D
Seminars:
Chair’s Opening Remarks 8:50 am
day: Conference Day Two
Panel Discussion: Personalized vs Off-the-shelf Cancer Vaccines: Evaluating the Advantages & Disadvantages for Better Clinical Efficacy 3:00 pm
Debating the feasibility of individualized cancer vaccines vs targeting shared neoantigens Highlighting successes in personalized cancer vaccines that prove clinical efficacy and viability Considering the future opportunities for cancer vaccines in personalized & off-the-shelf for positive patient responseRead more
day: Pre-Conference Focus Day